ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | 26.0% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margin improved 30 bps YoY to 28.5%. |
| Demand visibility | Strong; 882K+ patients served in Q1, up 25.1% YoY. |
| Management confidence | High, citing 'highest ever quarterly addition of surgical facilities'. |
Growth
Revenue grew 26.0% YoY to ₹614 Cr; PAT surged 44.6% YoY to ₹55 Cr. Surgeries performed increased by 15.5%.
Outlook
Planned addition of 42 more facilities in FY27 (12 in Q2, 30 in H2). Targeting 60 total new facilities for FY27.
Risks
Expansion maturity risks; emerging facilities currently contribute 21.0% of revenues and require scaling to optimize margins.
Last quarter's promises, checked
Delivered
- Guided 60 new facilities for FY27 → delivered 18 in Q1 (= BEAT)
- Targeted 30 surgical centers in FY26 → delivered 30 (= BEAT)
- Guided stable EBITDA margins → delivered 28.5% (+30 bps YoY) (= BEAT)
Partly delivered
- Guided 60 total new facilities for FY27 → 42 remaining to be added (= PARTIAL)
Investor Presentation filed with BSE, NSE: AGARWALEYE. Summary written with AI assistance from the document.
Dr. Agarwals Health Care Ltd: key numbers
- Share price
- ₹553.60
- Market cap
- ₹17,555 Cr
- Revenue (annual)
- ₹2,080 Cr
- Net profit (annual)
- ₹133.2 Cr
- P/E (TTM)
- 101.2×Sector 54.5×
- Promoter holding
- 32.33%-0.01% QoQ
- FII holding
- 49.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Agarwals Health Care Ltd
All →Dr. Agarwals Health Care Other Announcement
Dr. Agarwal's Health Care submitted ICRA's monitoring agency report for the quarter ended September 30, 2026. ICRA reports no material deviation in IPO proceeds utilisation.
Dr. Agarwals Health Care Employee Stock Options
Dr. Agarwal's Health Care allotted 54,728 equity shares to employees on exercise of ESOP 2022 options. Paid-up capital rose to 31,70,99,111 shares, with no cash consideration stated.
Dr. Agarwals Health Care Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%), network-led growth; India EBITDA margin flat near 28%.
Dr. Agarwals Health Care Management Change
Dr Agarwals Health Care reports Mr. Amar Agarwal's redesignation from Chairman and Non-Executive Director to Executive Director, effective 1 November 2026. The change was approved at a board meeting held on 5 November 2026.
Dr. Agarwals Health Care Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%). H1 FY27 revenue ₹1,269 Cr (+28.7%), PAT ₹112 Cr (+50.1%). Strategy is aggressive facility expansion, with 65 FY27E additions.
Dr. Agarwals Health Care Financial Results
Dr. Agarwal's H1 FY27 revenue rose 28.7% to Rs 1,269 crore; PAT rose 50.1% to Rs 112 crore. Amar Agarwal's executive chairman appointment awaits postal ballot approval.